Use of prostaglandin E1 (lipo-PGE1) to treat Raynaud's phenomenon associated with connective tissue disease: thermographic and subjective assessment.
Four patients with connective tissue disease who had been suffering from severe Raynaud's phenomenon were treated with an intravenous infusion of prostaglandin E1 (PGE1) and its effectiveness was assessed by thermography and a questionnaire approach. PGE1 in a lipid microsphere formulation (lipo-PGE1) produced a significantly greater increase in lesional skin temperature compared with treatment with PGE1 clathrated in alpha-cyclodextrin 12 months previously in the same group of patients. These results were supported by the subjective assessment obtained from the patients by questionnaire.
Katoh
K
K
First Department of Internal Medicine, Yokohama City University School of Medicine, Japan.
Kawai
T
T
Narita
M
M
Uemura
J
J
Tani
K
K
Okubo
T
T
D000293:Adolescent; D000328:Adult; D000527:Alprostadil / Q000009:adverse effects / Q000627:therapeutic use*; D003240:Connective Tissue Diseases / Q000150:complications* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D008297:Male; D008863:Microspheres; D010146:Pain / Q000188:drug therapy / Q000523:psychology; D011928:Raynaud Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012880:Skin Pigmentation; D012881:Skin Temperature / Q000187:drug effects; D011795:Surveys and Questionnaires
D000527:Alprostadil